Tag Archives | pharmacogenomics

Bio Investor Forum #2: T-Cell Therapies and Cancer Targets

Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology  is one of the hottest new areas of biopharmaceutical development and on October 7  BIO presented a Therapeutic Session on “T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets”. […]

Continue Reading 0

Green Day with Rayno Biopharmaceutical Stocks Up >2%

Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big winners are: Ariad (ARIA $6.17) up 9.98%, Pharmacyclics (PCYC $124.75) […]

Continue Reading

Biotech Stocks Get A Turbo Boost From Idenix Deal

Rally Retraces Correction Up To Mid-Point YTD Up until this week we have focused on large cap biopharmaceuticals because of revenue momentum, fair valuations and earnings. A risk -off sentiment due to lack of ASCO buzz and the Q1 speculative bubble downdraft has curbed gains. This week with  news of the Merck $3.9B deal for […]

Continue Reading

ASCO Update #4- No Boost For Oncology Stocks… Update-6/4 MDVN, PCYC, SGEN

Update 6/4 Snap- back rally and big green screen! Update 6/3….. Daily Performance-from list below 9 winners, 12 losers Rayno Biopharmaceutical Picks in bold— Winners: AGIO, INCY, SGEN, EPZM, MDVN, IMGN, GILD. CELG, PCYC. Losers: CLVS, ARIA, NLNK,CLDX, BLUE, LBIO, PBYI, KPTI, BMY, AZN, ICPT, XLRN. 30 Day winners: MDVN, PCYC, SGEN —— Rayno Large Cap […]

Continue Reading

Very Little Bounce in Biotech as ASCO Approaches… Update 2.. 5/22

Rally Developing-Green Screen Alert If you are underweight large cap biotech add FBT ($76.38) up 2%. Most of our large cap picks are up today: ABBV ALXN, BIIB,GILD,REGN. Reverse pattern from tuesday’s downdraft. ————– One of the worse days I have seen in small cap biotech in many months as speculation has ended and investors […]

Continue Reading